---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-075760"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:55:53.686416+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics stockholders elect three Class II directors and ratify PwC as auditor at 2024 annual meeting

## Summary
- Kristina Masson, Sharon Shacham, and Ivana Magovčević-Liebisch were elected as Class II directors with 24.6M, 23.3M, and 24.5M votes in favor, respectively.
- PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal year 2024 with 27.4M for, 6,036 against, and 10,308 abstentions.
- A quorum of 27.4M shares (88.81% of outstanding) was present or represented by proxy at the June 20, 2024 annual meeting.
- Broker non-votes on director elections totaled approximately 2.7M shares, with none on auditor ratification.

## SEC filing metadata
- accession: 0000950170-24-075760
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024075760/0000950170-24-075760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024075760/acrv-20240620.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-075760
- JSON: https://secwatch.observer/filing/0000950170-24-075760.json
- Plain text: https://secwatch.observer/filing/0000950170-24-075760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.